PBAC's latest decision on Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide: Recommended with restriction (2015). Considered for Treatment of HIV-1 infection in treatment-naïve patients and treatment-experienced patients with a clinical indication to switch components of therapy.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2015
Submissions
1
2015 → 2015
Eligible population
Treatment-naïve HIV-1 positive adults and paediatric patients 12 years and older without any known mutation associated with resistance to the individual components; also treatment-experienced virologically suppressed HIV-1 positive patients.
Therapy area
Infectious disease
Line of therapy
First-line
Evidence base
RCT
Primary endpoint
Proportion of patients with HIV RNA < 50 copies/mL